Navigation Links
Shire Continues to Deliver Excellent Growth From Core Products
Date:10/30/2009

DUBLIN, October 30 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company, announces results for the three months to September 30, 2009.

    Q3 2009 Financial Highlights

                                                               Q3 2009(1)

    Product sales                                        $603 million    -15%

    Product sales from core products(2)                  $532 million    +20%
    Product sales growth from core products at
    constant exchange rates(2)(3)                                        +23%

    Total revenues                                       $667 million    -14%

    Non GAAP operating income                            $134 million    -52%
    US GAAP operating income                              $92 million    -25%
    Non GAAP diluted earnings per ADS                           $0.49    -58%
    US GAAP diluted earnings per ADS                            $0.33  +$0.52

    (1) Figures compare Q3 2009 results with the same period in 2008.

    (2) Core products represent Shire's products excluding ADDERALL XR.

    (3) Sales growth at constant exchange rates ("CER"), which is a Non GAAP
        measure, is calculated after restating Q3 2009 results using Q3 2008
        average foreign exchange rates.

Angus Russell, Chief Executive Officer, commented:

"Shire continues to deliver excellent growth from its core products, which were up 20% over an exceptionally strong Q3 2008. This performance reflects our transformation in the past few years into a global biopharmaceutical company with a proven differentiated strategy and a balanced portfolio of new products which is protected by strong exclusivity and patent protection.

The growth of our core products and continued pro-active cost management are positioning us well to deliver on our unchanged guidance framework for 2009 and our aspiration of growing sa
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)... WOONSOCKET, R.I. , Jan. 15, 2014 MultiCell ... has filed a U.S. provisional patent application concerning composition ... formulations to achieve targeted tumor cell death.  ... very small noncoding double stranded RNA molecules (VSRNAs) which ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... Worldwide, Inc. (NYSE: OWW ) will host a conference call to discuss the ... Wednesday, May 5, 2010 at 10:00 a.m. EDT ( 9:00 a.m. CDT ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20070813/AQM125LOGO ) , ... A live webcast of the call can be accessed through the Orbitz Worldwide Investor Relations ...
... Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ), a biopharmaceutical company ... Paul F. Truex , Anthera,s President and Chief Executive Officer will present ... MA on Monday, May 3, 2010 at approximately ... , , ...
Cached Medicine Technology:Orbitz Worldwide, Inc. to Host First Quarter 2010 Earnings Call on May 5 2Orbitz Worldwide, Inc. to Host First Quarter 2010 Earnings Call on May 5 3Anthera Pharmaceuticals to Present at Deutsche Bank Securities' 35th Annual Health Care Conference 2
(Date:4/23/2014)... As evidence mounts showing the potential health benefits of ... people are taking supplements. And the chemical industry is ... supplements, health effects could deter growth, so the industry ... claims, according to the cover story in Chemical ... of the American Chemical Society. , Melody M. Bomgardner, ...
(Date:4/23/2014)... R.I. Parents and physicians concerned about an increase ... marijuana can breathe a sigh of relief. According to ... 20 years worth of data from states with and ... lead to increased use among adolescents. The study is ... Journal of Adolescent Health . , "Any time ...
(Date:4/23/2014)... has been a rapidly evolving pursuit with many ... in the research road, scientists have found a ... with the disease. The report, which appears in ... have important implications for developing novel treatments. , ... that for years, research has suggested a link ...
(Date:4/22/2014)... for low-income patients may ease the financial burden ... patient health, researchers have concluded. , A study ... avoid costs associated with insurance administration can help ... and emergency room visits, according to Mark Agee, ... The researchers estimated that the major hospital in ...
(Date:4/22/2014)... The International Communication Association will hold its ... The theme of the 2014 conference will explore ... and digital society. , Featuring over 2,300 academic ... Communication scholars representing over 40 countries, the ICA ... in the world. This year,s conference features sessions ...
Breaking Medicine News(10 mins):Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2
... be GI Awards, Honored for Commitment to Patient ... ... Procter and Gamble,Pharmaceuticals (P&G) is encouraging GI and Endoscopy professionals to,recognize outstanding ... support of the Society of Gastroenterology,Nurses and Associates, Inc. (SGNA) GI Nurses ...
... The apples and apple juice you consume may have ... in the body in the colon. New ... apple juice components actually enhance biological mechanisms that produce ... Using human fecal matter as the test substance, German ...
... MD: Artemisinins in Malaria Therapy, written by WRAIR researchers Dr. ... J. Weina (Division of Experimental Therapeutics at the WRAIR, Silver ... and recent developments in the treatment of one of the ... mankind malaria. , WRAIR, initially known as the Army ...
... Vitamin Stix Drink Mix, BROOKLYN, N.Y., March 26 ... your vitamins, 4C Totally Light2Go(TM) Vitamin Stix!,Packed with vitamins ... quickly becoming a staple for the gal on the ... three flavors of the 4C,Totally Light2Go(TM) Vitamin Stix have ...
... Increase of 126% ... -, - Removal of the Going Concern Qualification by its Independent ... Public Accountants - ... March 26 XELR8 Holdings, Inc. (Amex:,BZI), a provider of functional foods, beverages and nutritional,supplements, today ...
... SHANGHAI, China, March 26 /Xinhua-PRNewswire-FirstCall/ -- ... a leading developer,manufacturer and distributor of ... that its wholly owned subsidiary Shanghai ... an agreement with Shanghai,Disinfection Association (SDA), ...
Cached Medicine News:Health News:Nationwide Awards Recognize Nurses, Associates and Nursing Teams That Specialize in Gastroenterology and Endoscopy 2Health News:Nationwide Awards Recognize Nurses, Associates and Nursing Teams That Specialize in Gastroenterology and Endoscopy 3Health News:WRAIR investigators pioneering work on an exciting new class of antimalarial compounds 2Health News:Flavor and Vitamins on the Go 2Health News:XELR8 Holdings Announces Fiscal 2007 Financial Results 2Health News:XELR8 Holdings Announces Fiscal 2007 Financial Results 3Health News:XELR8 Holdings Announces Fiscal 2007 Financial Results 4Health News:XELR8 Holdings Announces Fiscal 2007 Financial Results 5Health News:XELR8 Holdings Announces Fiscal 2007 Financial Results 6Health News:XELR8 Holdings Announces Fiscal 2007 Financial Results 7Health News:XELR8 Holdings Announces Fiscal 2007 Financial Results 8Health News:Shanghai Disinfection Association and Linkwell Corporation Co-Establish the 'Shanghai Disinfection Association Laboratory Center' 2Health News:Shanghai Disinfection Association and Linkwell Corporation Co-Establish the 'Shanghai Disinfection Association Laboratory Center' 3
MedLook 3.0 is a medical billing software....
Managed care is a billing and tracking system....
... billing program dealing with the clerical aspects ... standard Health Insurance Claim Form, or CMS-1500. ... the internet. This means that you can ... home or work without using a web ...
... is a medical practice management ... tools and interfaces. This medical ... scheduling, patient demographics, insurance company ... paper and electronic claims filing ...
Medicine Products: